Hyperphosphatemia Secondary to the Selective Fibroblast Growth Factor Receptor 1–3 Inhibitor Infigratinib (BGJ398) Is Associated with Antitumor Efficacy in Fibroblast Growth Factor Receptor 3–altered Advanced/Metastatic Urothelial Carcinoma

Yung Lyou, Petros Grivas, Jonathan E. Rosenberg, Jean Hoffman-Censits, David I. Quinn, Daniel P. Petrylak, Matthew Galsky, Ulka Vaishampayan, Ugo De Giorgi, Sumati Gupta, Howard Burris, Jessica Rearden, Ai Li, Hao Wang, Maribel Reyes, Susan Moran, Siamak Daneshmand, Dean Bajorin, Sumanta K. Pal

Research output: Contribution to journal › Article › peer-review

Fingerprint

Dive into the research topics of 'Hyperphosphatemia Secondary to the Selective Fibroblast Growth Factor Receptor 1–3 Inhibitor Infigratinib (BGJ398) Is Associated with Antitumor Efficacy in Fibroblast Growth Factor Receptor 3–altered Advanced/Metastatic Urothelial Carcinoma'. Together they form a unique fingerprint.

Medicine & Life Sciences